TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21381872

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) without thrombin activation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with bovine anorganic bone mineral (ABM)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (PRP without ABM)
Number of subjects: 2
Study: 19240199

Group type: EXPERIMENTAL
Intervention: Extrastriate VRT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard VRT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NEI-VFQ
Number of subjects: 18
Study: 17202009

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 71

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 71
Study: 15595336

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both CGMS and SMBG
Number of subjects: 128
Study: 11915779

Group type: EXPERIMENTAL
Intervention: HMB (40mg/kg bodyweight/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 17
Study: 9415330

Group type: EXPERIMENTAL
Intervention: Tobramycin, polymyxin E, and amphotericin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (diphenhydramine, Maalox, and local analgesic)
Number of subjects: 0
Study: 7857700

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 623

Group type: COMPARATOR
Intervention: Not treated with adjuvant tamoxifen
Number of subjects: 623
Study: 3680604

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31944546

Group type: EXPERIMENTAL
Intervention: Higher starting dose of insulin glargine 100 U/mL (0.3 U/kg)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Standard starting dose of insulin glargine 100 U/mL (0.2 U/kg)
Number of subjects: 866
Study: 30084822

Group type: EXPERIMENTAL
Intervention: Thrombin-collagen combined with autologous platelet-rich plasma (PRP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 39
Study: 26537735

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation, 6 g daily (3.9 g n-3 PUFA) for 9 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Maize oil (MO) supplementation, 6 g daily for 9 months
Number of subjects: 36
Study: 23826645

Group type: EXPERIMENTAL
Intervention: Open-flap (OF) esthetic crown lengthening
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Flapless (FL) esthetic crown lengthening
Number of subjects: 28
Study: 24295143

Group type: EXPERIMENTAL
Intervention: Instructional and behavioral management strategies used by lower grade teachers
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Instructional and behavioral management strategies used by upper grade teachers
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Discrepancy scores of instructional and behavioral management strategies for upper grade teachers
Number of subjects: 317

Group type: COMPARATOR
Intervention: Years of teaching experience
Number of subjects: 317

Group type: COMPARATOR
Intervention: Years of teaching experience and grade-level assignment interaction
Number of subjects: 317
Study: 19897551

Group type: EXPERIMENTAL
Intervention: Capacity of Daily Living during the Morning (CDLM) questionnaire
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Global Chest Symptoms Questionnaire (GCSQ)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: CDLM and GCSQ scores
Number of subjects: 1100
Study: 18947140

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions in CRTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16151030

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Plasma viscosity, tPA, and d-dimer
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Fibrinogen and CRP
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Fibrinogen, CRP, plasma viscosity, tPA, d-dimer
Number of subjects: 6105
Study: 12814145

Group type: EXPERIMENTAL
Intervention: Coriolus versicolor polysaccharide peptide (PSP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 12640352

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rate Control
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ibutilide and Propafenone
Number of subjects: 42
Study: 10466566

Group type: EXPERIMENTAL
Intervention: Experimental group (informed of validation procedure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not informed of validation procedure)
Number of subjects: 0
Study: 7783313

Group type: EXPERIMENTAL
Intervention: TAZ/PIPC (2.5 g twice a day for 14 days)
Number of subjects: 164

Group type: COMPARATOR
Intervention: PIPC (2.0 g twice a day for 14 days)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: TAZ/PIPC
Number of subjects: 164

Group type: COMPARATOR
Intervention: PIPC
Number of subjects: 164
Study: 2128828

Group type: EXPERIMENTAL
Intervention: Combination therapy with leuprolide and flutamide
Number of subjects: 603

Group type: COMPARATOR
Intervention: Leuprolide alone
Number of subjects: 603
Study: 319662

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 to 10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (10 to 30 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (7.5 to 20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31250758

Group type: EXPERIMENTAL
Intervention: M2000 (mannuronic acid) 500mg orally twice per day for 12 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (15 healthy participants)
Number of subjects: 15
Study: 28237542

Group type: EXPERIMENTAL
Intervention: Single-implant retained overdentures
Number of subjects: 56

Group type: COMPARATOR
Intervention: Two-implant retained overdentures
Number of subjects: 56
Study: 26014298

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus RT/TMZ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus RT/TMZ
Number of subjects: 0
Study: 23176599

Group type: EXPERIMENTAL
Intervention: Self-management dietary counselling (SMDC) in Group A (n = 41)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Educational games in Group B (n = 41)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (Group C) (n = 40)
Number of subjects: 122
Study: 20495936

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment during gestation
Number of subjects: 246
Study: 18844508

Group type: EXPERIMENTAL
Intervention: CHIP intervention
Number of subjects: 348
Study: 16428535

Group type: EXPERIMENTAL
Intervention: Sugarless bubble gum
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sugared bubble gum
Number of subjects: 3

Group type: COMPARATOR
Intervention: No gum (Control)
Number of subjects: 3
Study: 15645905

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice containing calcium, phosphate, and sodium bicarbonate
Number of subjects: 113

Group type: COMPARATOR
Intervention: Commercially available fluoride and silica-containing dentifrice
Number of subjects: 113
Study: 11783068

Group type: EXPERIMENTAL
Intervention: Radical lymphadenectomy (RL)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Conventional lymph node dissection (control)
Number of subjects: 320
Study: 9373050

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5-5 mg, slow-release)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8207317

Group type: EXPERIMENTAL
Intervention: LMWH-Fluxum 3200 IUaXa daily (Group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Calcium heparin 5000 IU three times daily (Group B)
Number of subjects: 39
Study: 29574421

Group type: EXPERIMENTAL
Intervention: EmboTrap device
Number of subjects: 201
Study: 26728864

Group type: EXPERIMENTAL
Intervention: Consumption of canned food
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Use of alcoholic drinks at least weekly
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Consumption of fast food
Number of subjects: 184
Study: 25014621

Group type: EXPERIMENTAL
Intervention: High-speed resistance training (EG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-speed resistance training (SG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study: 22670252

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) and porous hydroxyapatite
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydroxyapatite and saline
Number of subjects: 60
Study: 20027119

Group type: EXPERIMENTAL
Intervention: Dual-source CT (DSCT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 29
Study: 18433425

Group type: EXPERIMENTAL
Intervention: yohimbine 16.2 mg p.o. t.i.d. for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 30
Study: 16154274

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (4-6mg dosed by ideal body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morphine minus placebo analgesia calculation
Number of subjects: 60
Study: 14989112

Group type: EXPERIMENTAL
Intervention: Withdrawal of inhaled corticosteroid (ICS) therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inhaled corticosteroid (ICS) therapy continued
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Withdrawal of ICS therapy
Number of subjects: 19
Study: 10634835

Group type: EXPERIMENTAL
Intervention: Patient triggered ventilation
Number of subjects: 386

Group type: COMPARATOR
Intervention: Conventional fast rate ventilation
Number of subjects: 386
Study: 8894800

Group type: EXPERIMENTAL
Intervention: Marvelon
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Diane
Number of subjects: 66
Study: 1517921

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (2000 IU retinyl palmitate, n = 27)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline placebo (n = 22)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (2000 IU retinyl palmitate)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 49
Study: 6383927

Group type: EXPERIMENTAL
Intervention: Monotard MC + Actrapid MC (human insulin)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Monotard HM + Actrapid HM (porcine insulin)
Number of subjects: 135
Study: 31345007

Group type: EXPERIMENTAL
Intervention: Absolute Pro® (ABS)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Complete SE® (COM)
Number of subjects: 197
Study: 30052317

Group type: EXPERIMENTAL
Intervention: Topical application of a representative antiperspirant formulation containing 26 Al chlorohydrate (ACH)
Number of subjects: 12
Study: 26982078

Group type: EXPERIMENTAL
Intervention: Quincke needle
Number of subjects: 126

Group type: COMPARATOR
Intervention: Whitacre needle
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Positive aspiration test
Number of subjects: 126
Study: 24642190

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation with a volar locking plate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Closed reduction followed by plaster immobilisation
Number of subjects: 90
Study: 22941746

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for UHR patients plus treatment as usual (CBTuhr)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 201
Study: 19838862

Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) 30 mg/day (15 mg twice per day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Donepezil 10 mg/day (5 mg twice per day)
Number of subjects: 54
Study: 18023680

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with intensive medical therapy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Surgical ventricular reconstruction plus coronary artery bypass grafting
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Medical therapy and coronary artery bypass grafting
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Medical therapy and coronary artery bypass grafting with surgical ventricular reconstruction
Number of subjects: 1000
Study: 16244269

Group type: EXPERIMENTAL
Intervention: Early information arm with MR results provided within 48 hours
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control arm where patients and physicians were blinded to MR results
Number of subjects: 246
Study: 12045679

Group type: EXPERIMENTAL
Intervention: NNRTI-containing triple therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 5-drug regimen
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PI-containing triple therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Double NRTI therapy
Number of subjects: 43
Study: 9528731

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily for 12 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Immediate-release niacin 1 g three times daily for 12 weeks
Number of subjects: 108
Study: 8558884

Group type: EXPERIMENTAL
Intervention: Paired comparisons method
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Category rating method
Number of subjects: 80
Study: 2104939

Group type: EXPERIMENTAL
Intervention: Indomethacin (Indo) 100 mg IV 6 hours postoperatively and 3 x 50 mg IV Indo over 24 hours on postoperative days 1, 2, 3, 4
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Indomethacin (Indo)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 43
Study: 853204

Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 39
Study: 30702021

Group type: EXPERIMENTAL
Intervention: Self-expanding nitinol stents
Number of subjects: 105

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 105
Study: 29386335

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 52
Study: 27591917

Group type: EXPERIMENTAL
Intervention: Defined symptom-change trajectories (linear, log-linear, one-step) during acute-phase cognitive therapy
Number of subjects: 220
Study: 24973196

Group type: EXPERIMENTAL
Intervention: Individualized educational intervention (40-min one-to-one session using motivational interviewing techniques, reinforced at 1 and 6 months)
Number of subjects: 1947

Group type: COMPARATOR
Intervention: Usual in-hospital education (control group)
Number of subjects: 1947
Study: 21691843

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2677
Study: 20594395

Group type: EXPERIMENTAL
Intervention: 150 g farmed trout raised on marine feed
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 150 g farmed trout raised on vegetable feed
Number of subjects: 68

Group type: COMPARATOR
Intervention: 150 g chicken
Number of subjects: 68
Study: 17321529

Group type: EXPERIMENTAL
Intervention: 400 mug of oral misoprostol
Number of subjects: 622

Group type: COMPARATOR
Intervention: 5 U of intravenous oxytocin
Number of subjects: 622
Study: 16401781

Group type: EXPERIMENTAL
Intervention: Vitreoretinal surgery (scleral buckling and/or vitrectomy)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Scleral buckle only
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Observation (no surgery)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Vitreoretinal surgery for stage 4A retinal detachment
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Vitreoretinal surgery for stage 5 disease
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Overall outcomes of retinal detachment due to ROP
Number of subjects: 401
Study: 12418945

Group type: COMPARATOR
Intervention: Clinic heart rate greater than 79 bpm
Number of subjects: 4682

Group type: COMPARATOR
Intervention: Clinic heart rate
Number of subjects: 4682

Group type: COMPARATOR
Intervention: Ambulatory heart rate
Number of subjects: 4682
Study: 10352633

Group type: EXPERIMENTAL
Intervention: Unlicensed homes
Number of subjects: 301

Group type: COMPARATOR
Intervention: Licensed facilities
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Unlicensed homes - Physical care
Number of subjects: 301

Group type: COMPARATOR
Intervention: Licensed facilities - Physical care
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Unlicensed homes - Medical management
Number of subjects: 301

Group type: COMPARATOR
Intervention: Licensed facilities - Medical management
Number of subjects: 301
Study: 7737719

Group type: EXPERIMENTAL
Intervention: 5 mg oral bromocriptine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2202544

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diclofenac (75‐150 mg daily)
Number of subjects: 80
Study: 7021994

Group type: EXPERIMENTAL
Intervention: Furosemide (F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water-bath immersion
Number of subjects: 0
Study: 31182150

Group type: EXPERIMENTAL
Intervention: Robotic-assisted esophagectomy (RE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic esophagectomy (VATE)
Number of subjects: 0
Study: 28635359

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IVPCA)
Number of subjects: 90
Study: 26009782

Group type: EXPERIMENTAL
Intervention: Single-session brief motivational interview (BMI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 60
Study: 23603204

Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV16/18
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV16/18/45
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative for any of the three combinations
Number of subjects: 0
Study: 21093145

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d)
Number of subjects: 4844

Group type: EXPERIMENTAL
Intervention: Combination of dutasteride (0.5 mg/d) and tamsulosin (0.4 mg/d)
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg/d)
Number of subjects: 4844
Study: 19275490

Group type: EXPERIMENTAL
Intervention: ZDV/3TC/LPV/r
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: NVP/LPV/r
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ZDV/3TC/LPV/r and NVP/LPV/r
Number of subjects: 37
Study: 17252176

Group type: EXPERIMENTAL
Intervention: Early rehabilitation by a rehabilitation specialist, including tailored treatment for post-concussion symptoms (PCS).
Number of subjects: 395

Group type: COMPARATOR
Intervention: Regular care (Control group).
Number of subjects: 395
Study: 15490827

Group type: EXPERIMENTAL
Intervention: Computerized tongue inspection method using Bayesian networks
Number of subjects: 525

Group type: COMPARATOR
Intervention: Traditional tongue diagnosis
Number of subjects: 525
Study: 10562778

Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 29)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Isoflurane (n = 22)
Number of subjects: 51
Study: 8909010

Group type: EXPERIMENTAL
Intervention: Salmeterol (SM) 100 micrograms (four puffs, 25 micrograms per actuation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol (SB) 200 micrograms (four puffs, 50 micrograms per actuation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P) (four puffs)
Number of subjects: 10
Study: 1921253

Group type: EXPERIMENTAL
Intervention: Low salt diet of 20 mmol sodium per day
Number of subjects: 147

Group type: COMPARATOR
Intervention: High salt diet of 300 mmol sodium per day
Number of subjects: 147
Study: 6354604

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined therapy (Atenolol 100 mg + Indapamide 2.5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31923300

Group type: EXPERIMENTAL
Intervention: Immediate loading of mini-implants with housings and O-rings (insertion torque ≥ 35 Ncm) or soft relining material (insertion torque < 35 Ncm)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Delayed loading of mini-implants (group B)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups after all housings were picked up
Number of subjects: 76
Study: 30934863

Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (SP)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 501
Study: 27885399

Group type: EXPERIMENTAL
Intervention: Oral selexipag (400 μg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous selexipag (200 μg)
Number of subjects: 16
Study: 26200270

Group type: EXPERIMENTAL
Intervention: Folate receptor-positive circulating tumor cells (CTCs) detection using ligand-targeted PCR technique
Number of subjects: 756

Group type: COMPARATOR
Intervention: CTCs
Number of subjects: 756

Group type: COMPARATOR
Intervention: Model combining CTCs with carcinoembryonic antigen, neuron-specific enolase, and Cyfra21-1
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: CTC levels
Number of subjects: 756
Study: 22657533

Group type: EXPERIMENTAL
Intervention: PZQ syrup
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Crushed PZQ tablet
Number of subjects: 1144
Study: 20531235

Group type: COMPARATOR
Intervention: Positive feedback group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative feedback group
Number of subjects: 0